Pentobarbital will decrease the level or effect of roflumilast ort affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration not recommended; strong cytochrome P450 enzyme inducers decrease systemic exposure to roflumilast and may reduce the therapeutic effectiveness The effect of the resultant decreased blood levels of griseofulvin on therapeutic respon... https://holdenanyjv.blog-ezine.com/30134781/top-riktlinjerna-från-är-natriumpentobarbital-ett-kontrollerat-läkemedel